Frontlight ResearchEarly access
Active, not recruitingNo phase
COMPASSION S3 Post-Approval Study
Key facts
- Who runs it
- Edwards Lifesciences
- Where
- Aurora, Austin, Birmingham, Boston, Charlottesville, Cincinnati, Columbus, Dallas, Durham, Los Angeles, Minneapolis, New York, Newark, Oak Lawn, Philadelphia, Pittsburgh, Salt Lake City, and St Louis, United StatesSee the 19 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 150 people enrolled
- Started
- 13 Apr 2021
- Expected to end
- Aug 2030
- Type of study
- Observational
- Treatments tested
- SAPIEN 3 THV
- Record updated
- 3 February 2026
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Dysfunctional RVOT conduit or previously implanted surgical valve
- RVOT/PV with ≥ moderate regurgitation and/or a mean RVOT/PV gradient of ≥ 35 mmHg
Who cannot take part
- Active bacterial endocarditis or other active infections
- Inability to tolerate an anticoagulation/antiplatelet regimen
Where in United States
- Children's Hospital of ColoradoAurora, United States
- Dell Children'sAustin, United States
- University of AlabamaBirmingham, United States
- Boston Children's HospitalBoston, United States
- University of VirginiaCharlottesville, United States
- Cincinatti Children's HospitalCincinnati, United States
- Nationwide Children's HospitalColumbus, United States
- Children's Health DallasDallas, United States
- Duke UniversityDurham, United States
- Cedars SinaiLos Angeles, United States
- Minneapolis HeartMinneapolis, United States
- Columbia University Medical Center/NYPHNew York, United States
- Mount SinaiNew York, United States
- Newark Beth Israel Medical CenterNewark, United States
- Advocate Childrens HospitalOak Lawn, United States
- Children's Hospital of PhiladelphiaPhiladelphia, United States
- University of Pittsburgh Medical CenterPittsburgh, United States
- Primary Children'sSalt Lake City, United States
- St. Louis Children's HospitalSt Louis, United States
About the trial
What the trial wants to find out
This study will monitor device performance and outcomes of the SAPIEN 3 Transcatheter Heart Valve (THV) System in subjects with a dysfunctional right ventricular outflow tract (RVOT) conduit or previously implanted surgical valve in the pulmonic position with a clinical indication for intervention.
The group in the trial
- TPVR
Subjects with a dysfunctional RVOT conduit or previously implanted surgical valve in the pulmonic position will undergo transcatheter pulmonary valve replacement (TPVR).
Treatment: SAPIEN 3 THV
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Congenital Multicenter Trial of Pulmonic Valve Dysfunction Studying the SAPIEN 3 Interventional THV Post-Approval Study
- Record updated
- 3 February 2026